ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO002

A CKD Awareness Campaign and mHealth Education to Improve Knowledge and Quality of Life Among CKD Patients in Bangladesh: A Randomized Controlled Trial

Session Information

  • Educational Research
    November 03, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Educational Research

  • 900 Educational Research


  • Sarker, Mohammad Habibur rahman, International Centre for Diarrhoeal Disease Research Bangladesh, Dhaka, Dhaka District, Bangladesh

Chronic kidney disease (CKD) is linked to major health consequences and a poor quality of life. Despite the fact that CKD is becoming more prevalent, public knowledge of the disease remains low. We aimed to evaluate the outcome of a health education intervention designed to enhance knowledge, health-related quality of life (QOL), and healthy lifestyle among CKD adults.


This was a parallel-group (1:1) randomized controlled trial in Bangladesh that compared two groups of CKD patients. Adults individual with CKD (stages 1-3) were enrolled in November 2020 and randomly assigned to intervention or control group. The intervention group received health education through a CKD awareness campaign and mHealth technologies, whereas the control group received usual care, and was observed for six months. Primary Outcome was improved scores on the CKD knowledge questionnaire and secondary outcomes were improved QOL and changes in the level of blood pressure (BP), BMI, fasting blood sugar (FBS), cholesterol, triglyceride and serum uric acid.


We enrolled 126 patients (control, n=63, intervention, n=63) in the study and performed intention to treat analysis. The analyses included repeated measures ANOVA and results were observed to be significantly different in case of within-group (P<.001), between groups (P<.001) and interaction of group × time factor (P<.001) in terms of knowledge score. Diastolic BP and BMI showed significant differences arising from within groups (P<.001, P=.01 respectively) and in interaction of group × time factor (P=.001, P=.02 respectively); hip circumferences showed significant difference arising from within groups (P=.03 respectively) and between groups (P=.02). Moreover, systolic BP and waist circumference showed significant differences within groups (P<.001, P=.003 respectively). Regarding laboratory findings, from baseline to six months, the mean (±SD) FBS decreased by 0.51 ± 3.77mg/dl in the intervention group and by 0.10 ± 1.44 g/dl in the control group (P=.03).


The health education strategy, which included a campaign and mHealth, showed promise for enhancing CKD knowledge and controlling their FBS and BP among CKD patients. The combined health education initiatives give evidence for scaling them up in Bangladesh and possibly other low- and middle-income countries.


  • Other NIH Support